Phase 1 · NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects
CompletedVerified
Registry record
Trial details
- Trial
- A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- ClinicalTrials.gov ID
- NCT03841630
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 45
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 21 Years – 65 Years
- Locations
- 1 site · Singapore
- Study start
- 13 Mar 2019
- Primary completion
- 25 Jul 2019
- Study completion
- 25 Jul 2019
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 6 Aug 2019
Endpoints
Primary
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary
Pharmacokinetics: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3437943; Pharmacokinetics: Maximum Concentration (Cmax) of LY3437943; Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3437943